Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

NCT05204173 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05204173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05204173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 20, 2021
Completion date
December 31, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iv, peritoneal metastases